# Biotech Daily Digest — 2025-11-09

**2 items from 2 sources**

## Summary by Source

- Endpoints News: 1 item
- Regeneron Press Releases: 1 item


## Endpoints News

- **[#AHA25: Amgen’s cholesterol drug cuts first-time cardiovascular events by a quarter](https://endpoints.news/aha25-amgens-cholesterol-drug-cuts-first-time-cardiovascular-events-by-a-quarter/)**  
  _Sat, 08 Nov 2025 15:10:59 +0000_  
  Amgen on Saturday said its cholesterol-lowering drug Repatha cut cardiovascular events by 25% when added on top of standard therapy in high-risk patients who have never had a heart attack or stroke.

 Repatha is already ...


## Regeneron Press Releases

- **[Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet](https://investor.regeneron.com/news-releases/news-release-details/phase-2-trials-demonstrating-antithrombotic-effect-two-novel)**  
  _Sat, 08 Nov 2025 10:46:00 -0500_  
  Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement Trial results consistent with prospective design of these antibodies to have distinct profiles – one to provide
